Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
2018
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors
2015 StandoutNobel
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
2015 Standout
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
2014
Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
2013
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
2008
Reporting methods in studies developing prognostic models in cancer: a review
2010
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
2014
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
2015 Standout
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Towards better clinical prediction models: seven steps for development and an ABCD for validation
2014 Standout
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets
2013
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Breast Cancer Stem Cells: Current Advances and Clinical Implications
2015
Percutaneous Drainage Compared with Surgery for Hepatic Hydatid Cysts
1997
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer
2012
Echinococcosis
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Circulating tumour cells and cell-free DNA as tools for managing breast cancer
2013
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
The Evolving Landscape of Brain Metastasis
2018
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Acute kidney injury
2019 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Percutaneous treatment of hydatid cysts of the liver: long-term results.
1999
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
2005 Standout
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial
2013
Fertility Preservation Methods in Breast Cancer
2012
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Platinum Compounds in the Treatment of Advanced Breast Cancer
2001
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Cisplatin and its analogues in the treatment of advanced breast cancer: a review
1992
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Reporting performance of prognostic models in cancer: a review
2010
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
Mechanisms of Bone Metastasis
2004 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Factors affecting the prognosis of breast cancer patients with brain metastases
2008
Clinical applications of the CellSearch platform in cancer patients
2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Biology, vulnerabilities and clinical applications of circulating tumour cells
2022
Breast cancer metastasis: markers and models
2005 Standout
Noncovalent Functionalization of Graphene and Graphene Oxide for Energy Materials, Biosensing, Catalytic, and Biomedical Applications
2016 Standout
PAMAM Dendrimer-Based Multifunctional Conjugate for Cancer Therapy: Synthesis, Characterization, and Functionality
2006
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
2014
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
2017
Biological, Epidemiological, and Clinical Aspects of Echinococcosis, a Zoonosis of Increasing Concern
2004 Standout
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Female Reproductive Health After Childhood, Adolescent, and Young Adult Cancers: Guidelines for the Assessment and Management of Female Reproductive Complications
2013
Cancer treatment and survivorship statistics, 2019
2019 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Nephrotoxicity of anticancer treatment
2016
When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer
2001
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Skeletal complications of malignancy
1997 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
2015 Standout
Potential Years of Life Lost Due to Urogenital Cancer in the United States: Trends From 1972 to 2006 Based on Data From the SEER Database
2012
Cardiac toxicity in cancer survivors
2013
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Works of Stefania Gori being referenced
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
2008
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
2011
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
2012
HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results
2005
Germ cell tumours of the testis
2004
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial
2007
A population survival model for breast cancer
2004
Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer
2011
Chemotherapy with cis-Platin, Doxorubicin, and Cyclophosphamide (CAP) in Patients with Metastatic Breast Cancer
1989
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
2004
CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
2015
Induction Chemotherapy with Cisplatin, Doxorubicin, and Cyclophosphamide (CAP) in a Combined Modality Approach for Locally Advanced and Inflammatory Breast Cancer
1996
Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer
2012
Long-Term Results in Patients with Advanced Epithelial Ovarian Carcinoma Treated with a Combination of Cisplatin, Doxorubicin, and Cyclophosphamide
1997
Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis
2012
Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda Trial
2014
Central Nervous System Metastases in HER-2–Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors
2007
Vindesine and mitomycin c in chemotherapy refractory advanced breast cancer
1986
C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients
1999
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival
2015
Weekly Paclitaxel in Metastatic Breast Cancer Patients: A Phase II Study
2002
Cytology in the percutaneous treatment of hydatid cysts. A report of four cases.
1993